[Hengrui Pharmaceutical: notice of approval for Clinical trial of HRS-5041 tablets] June 5, Hengrui Pharmaceutical announced that the company and its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a "notice of approval for Clinical trial of drugs" for HRS-5041 tablets and will carry out clinical trials in the near future.